NHS England 11 February 2020
- Decisions on which new specialised treatments should be routinely commissioned:
- NHS England has agreed to continue funding two stereotactic ablative radiotherapy (SABR) policies for patients with metachronous extracranial oligometastatic cancer (all ages), and for hepatocellular carcinoma (adults)
- Temozolomide as adjuvant treatment for people with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (adults)
- Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Human coagulation factor X for hereditary factor X deficiency (all ages)
- Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
